Business Description
Evolus Inc
NAICS : 325411
SIC : 2833
ISIN : US30052C1071
Total Employee Number:
350Description
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.3 | |||||
Equity-to-Asset | -0.13 | |||||
Debt-to-Equity | -5.73 | |||||
Debt-to-EBITDA | -12.04 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.75 | |||||
Beneish M-Score | -2.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.3 | |||||
3-Year EBITDA Growth Rate | 31.4 | |||||
3-Year EPS without NRI Growth Rate | 16.2 | |||||
3-Year FCF Growth Rate | 20.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.03 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.29 | |||||
9-Day RSI | 55.84 | |||||
14-Day RSI | 57.89 | |||||
3-1 Month Momentum % | 53.06 | |||||
6-1 Month Momentum % | 9.84 | |||||
12-1 Month Momentum % | -27.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.04 | |||||
Quick Ratio | 1.68 | |||||
Cash Ratio | 0.73 | |||||
Days Inventory | 86.3 | |||||
Days Sales Outstanding | 61.08 | |||||
Days Payable | 75.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.9 | |||||
Shareholder Yield % | -6.13 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.06 | |||||
Operating Margin % | -10.42 | |||||
Net Margin % | -14.39 | |||||
EBITDA Margin % | -4.54 | |||||
FCF Margin % | -14.95 | |||||
OCF Margin % | -12.2 | |||||
ROA % | -19.6 | |||||
ROIC % | -28.12 | |||||
3-Year ROIIC % | 90.68 | |||||
ROC (Joel Greenblatt) % | -74.03 | |||||
ROCE % | -14.99 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 3 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 562.86 | |||||
PS Ratio | 1.5 | |||||
EV-to-EBIT | -24.69 | |||||
EV-to-Forward-EBIT | -45.28 | |||||
EV-to-EBITDA | -42 | |||||
EV-to-Forward-EBITDA | -78.15 | |||||
EV-to-Revenue | 1.91 | |||||
EV-to-Forward-Revenue | 1.72 | |||||
EV-to-FCF | -12.83 | |||||
Price-to-GF-Value | 0.51 | |||||
Earnings Yield (Greenblatt) % | -4.05 | |||||
FCF Yield % | -9.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evolus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 259.299 | ||
| EPS (TTM) (€) | -0.576 | ||
| Beta | 1.9716 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.31 | ||
| Volatility % | 63.13 | ||
| 14-Day RSI | 57.89 | ||
| 14-Day ATR (€) | 0.114612 | ||
| 20-Day SMA (€) | 5.8823 | ||
| 12-1 Month Momentum % | -27.72 | ||
| 52-Week Range (€) | 3.42 - 8.3 | ||
| Shares Outstanding (Mil) | 65.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evolus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evolus Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 122 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 29 days | ||
| General meeting for 2026 | 2026-06-11 08:00 | 5.80 (+1.22%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 12:50 | 5.26 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 16:30 | 4.39 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 4.39 (+0.00%) | ||
| Needham Virtual Healthcare Conference | 2026-04-14 15:45 | 3.74 (+3.75%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-11 11:20 | 4.54 (+0.00%) |
Show
Entries
Evolus Inc Frequently Asked Questions
What is Evolus Inc(FRA:EVL)'s stock price today?
The current price of FRA:EVL is €6.01. The 52 week high of FRA:EVL is €8.30 and 52 week low is €3.42.
When is next earnings date of Evolus Inc(FRA:EVL)?
The next earnings date of Evolus Inc(FRA:EVL) is 2026-08-05 Est..
Does Evolus Inc(FRA:EVL) pay dividends? If so, how much?
Evolus Inc(FRA:EVL) does not pay dividend.
Press Release
Articles on Evolus Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers